Home Tags Clinical Trials
Clinical Trials Related Content
A study examining older people in the UK found that only one dose of the AstraZeneca vaccine is atleast 60% effective for people aged 70 and over.
Israel faced international criticism on their refusal to vaccine Palestinians - now, the country will begin rolling out Pfizer shots to some Palestinians who have work permits.
The US Food and Drug Administration (FDA) approved the Johnson & Johnson vaccine, with an efficacy of 86%, as the next to be rolled out across the US.
Israel is currently leading the world in COVID vaccination, with real-world data to suggest that the Pfizer vaccine is working to stop 92% of severe COVID cases.
New data from the REACT study finds that 14% of the UK population have antibodies against COVID-19 now, but that vaccine hesitancy is currently highest in London.
The Californian COVID mutation appears to be as infectious as the UK or South African mutations - but does it have the potential to be more deadly?
New documents from the FDA show that the Johnson & Johnson vaccine appears to be 86% effective against COVID-19 - signalling that it will soon be approved in the US.
Early stage data from the vaccine rollout in the UK appears to show that COVID hospitalisation and death are reduced by over 75% in people with the Pfizer vaccine.
The Sinovac COVID vaccine was revealed to be working at 50.4% efficacy by the Butantan Institute last month, but new data suggests that this could actually be 62%.
COVID brought the idea of mRNA vaccines to the attention of the world - now, cancer researchers are investigating how a similar vaccine could stop tumours in a single treatment.
The Pfizer and BioNTech vaccine appears to be significantly less efficient against the South African mutation, but can still stop hosts from experiencing severe COVID and dying from the virus.
New data from the REACT study finds that the number of COVID cases in hospitals is higher than it was in April 2020, but that infection rates are substantially decreasing across the country.
The New Jersey-based drugmaker created a COVID-19 vaccine that works at 66% efficiency in one dose, which they have sent to the EU for approval.
A research team at MIT have created a machine-learning strategy to identify existing drugs that could be repurposed to fight COVID-19 in elderly patients.
Here, we use science to dissect some of the rumours about the side effects of the AstraZeneca and Oxford University vaccine.
The World Health Organisation have suggested that the Oxford and AstraZeneca vaccine can be safely used for all age groups, including those aged 65 and over.
The new results led to the South African Government suspending use of AstraZeneca in their vaccination programme, as it is no longer able to stop the mutation - but could still prevent hospitalisation and fatality.
Interim data from Phase 3 clinical trials show that Russia's Sputnik V vaccine is capable of a 91.6% efficacy against COVID-19.
European regulators have approved their third vaccine, AstraZeneca - which comes after a week of tense communications between the two parties.
Phase Three data from the UK trial shows that Novavax still works powerfully against the UK mutation, with a less intense impact on the South African mutation at 60%.